Heptares Therapeutics Ltd. - Product Pipeline Review - 2013

Market: Pharmaceuticals and Healthcare

Global, 36 pages report, published by Global Markets Direct

Keywords : Current R&D Portfolio of Heptares Therapeutics Ltd.; Heptares Therapeutics Ltd. - Key Therapeutics; Heptares Therapeutics Ltd. - Pipeline Overview and Promising Molecules; Heptares Therapeutics Ltd. - News; Heptares Therapeutics Ltd. - Latest Updates; Heptares Therapeutics Ltd. - Pipeline; Heptares Therapeutics Ltd. - Discontinued/Dormant Projects

Report ThumbnailAugust-2013
Heptares Therapeutics Ltd. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Heptares Therapeutics Ltd. - Product Pipeline Review - 2013” provides data on the Heptares Therapeutics Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Heptares Therapeutics Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Heptares Therapeutics Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Heptares Therapeutics Ltd. - Brief Heptares Therapeutics Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Heptares Therapeutics Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Heptares Therapeutics Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Heptares Therapeutics Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Heptares Therapeutics Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Heptares Therapeutics Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Heptares Therapeutics Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Heptares Therapeutics Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Heptares Therapeutics Ltd. and identify potential opportunities in those areas.
  • List of Figures
  • Heptares Therapeutics Ltd. - Pipeline by Indication, 2013 7
  • Heptares Therapeutics Ltd. - Pipeline by Stage of Development, 2013 9
  • Heptares Therapeutics Ltd. - Monotherapy Products in Pipeline, 2013 10
  • Heptares Therapeutics Ltd. - Pipeline By Therapeutic Class, 2013 26
  • Heptares Therapeutics Ltd. - Pipeline Products By Mechanism of Action, 2013 30
  • List of Tables
  • Heptares Therapeutics Ltd., Key Information 5
  • Heptares Therapeutics Ltd., Key Facts 5
  • Heptares Therapeutics Ltd. - Pipeline by Indication, 2013 8
  • Heptares Therapeutics Ltd. - Pipeline by Stage of Development, 2013 9
  • Heptares Therapeutics Ltd. - Monotherapy Products in Pipeline, 2013 10
  • Heptares Therapeutics Ltd. - Preclinical, 2013 11
  • Heptares Therapeutics Ltd. - Discovery, 2013 12
  • Heptares Therapeutics Ltd. - Pipeline By Therapeutic Class, 2013 27
  • Heptares Therapeutics Ltd. - Pipeline By Target, 2013 28
  • Heptares Therapeutics Ltd. - Pipeline By Route of Administration, 2013 29
  • Heptares Therapeutics Ltd. - Pipeline Products By Mechanism of Action, 2013 31
  • Heptares Therapeutics Ltd. - Recent Pipeline Updates, 2013 32
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Heptares Therapeutics Ltd. Snapshot 6
  • Heptares Therapeutics Ltd. Overview 6
  • Key Information 6
  • Key Facts 6
  • Heptares Therapeutics Ltd. - Research and Development Overview 7
  • Key Therapeutic Areas 7
  • Heptares Therapeutics Ltd. - Pipeline Review 10
  • Pipeline Products by Stage of Development 10
  • Pipeline Products - Monotherapy 11
  • Heptares Therapeutics Ltd. - Pipeline Products Glance 12
  • Heptares Therapeutics Ltd. - Early Stage Pipeline Products 12
  • Preclinical Products/Combination Treatment Modalities 12
  • Discovery Products/Combination Treatment Modalities 13
  • Heptares Therapeutics Ltd. - Drug Profiles 14
  • Antibody Targeting GPCR 14
  • Product Description 14
  • Mechanism of Action 14
  • R&D Progress 14
  • CGRP Antagonist 15
  • Product Description 15
  • Mechanism of Action 15
  • R&D Progress 15
  • CXCR4 Antagonist 16
  • Product Description 16
  • Mechanism of Action 16
  • R&D Progress 16
  • Drug Targeting Muscarinic M1/4 17
  • Product Description 17
  • Mechanism of Action 17
  • R&D Progress 17
  • Drug Targeting Orexin 1 18
  • Product Description 18
  • Mechanism of Action 18
  • R&D Progress 18
  • Drug Targeting Orexin 1/2 19
  • Product Description 19
  • Mechanism of Action 19
  • R&D Progress 19
  • GLP-1 Receptor Agonist 20
  • Product Description 20
  • Mechanism of Action 20
  • R&D Progress 20
  • GPR-39 Agonist 21
  • Product Description 21
  • Mechanism of Action 21
  • R&D Progress 21
  • mGluR2 Modulator 22
  • Product Description 22
  • Mechanism of Action 22
  • R&D Progress 22
  • mGluR5 Antagonist 23
  • Product Description 23
  • Mechanism of Action 23
  • R&D Progress 23
  • Muscarinic 1 Receptor Agonist 24
  • Product Description 24
  • Mechanism of Action 24
  • R&D Progress 24
  • Undisclosed Compound 1 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • Undisclosed Compound 2 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • Heptares Therapeutics Ltd. - Pipeline Analysis 29
  • Heptares Therapeutics Ltd. - Pipeline Products by Therapeutic Class 29
  • Heptares Therapeutics Ltd. - Pipeline Products By Target 31
  • Heptares Therapeutics Ltd. - Pipeline Products by Route of Administration 33
  • Heptares Therapeutics Ltd. - Pipeline Products By Mechanism of Action 34
  • Heptares Therapeutics Ltd. - Recent Pipeline Updates 36
  • Heptares Therapeutics Ltd. - Locations And Subsidiaries 38
  • Head Office 38
  • Appendix 39
  • Methodology 39
  • Coverage 39
  • Secondary Research 39
  • Primary Research 39
  • Expert Panel Validation 39
  • Contact Us 40
  • Disclaimer 40

Please select a license type

Share

Related Products

Global Markets DirectHeptares Therapeutics Ltd. - Product Pipeline Review - 2013Product ThumbnailHeptares Therapeutics Ltd. - Product Pipeline Review - 2013, Industry ReportProduct #: 113360
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved